Saphnelo (anifrolumab) is a one-of-a-kind therapy by AstraZeneca for the treatment of moderate to severe systemic lupus erythematosus (SLE). In December of 2023, Saphnelo was approved for coverage under the Ontario Exceptional Access Program (EAP).
SLE is an autoimmune condition in which the immune system creates widespread inflammation in many parts of the body. This leads to a variety of symptoms which include rashes, fever, and pain in the joints. Saphnelo works by blocking the activity of the type 1 interferon receptor, stopping the signaling (the type 1 interferons) that would lead to inflammation. As a result, the immune system can control the inflammation, and improve symptoms and the quality of life for patients with SLE.
Saphnelo is given as an intravenous infusion over 30 minutes, every 4 weeks. Currently, it is only approved to be used in adults.
The Charlton Health team is excited to work with specialists to bring Saphnelo to our patients with lupus.
Parvinder Sahota is a clinical pharmacist and a recent graduate from the University of Toronto. He enjoys learning about the ever-evolving field of autoimmune conditions and their treatment options.
This week, many will return to school, and it's no secret that the back-to-school season…
Staying well hydrated is important in every season, but it becomes especially crucial during thesummer.…
Last week, on July 28th, we observed World Hepatitis Day, a day dedicated to raising…
Summer is a great time to get out and see new sights. Whether you're planning…
Now that the warmer weather is here, many of us are spending more time enjoying…
Biosimilars are becoming more common in Canada, offering patients trusted alternatives to the originator biologic medication. Biosimilars…